CA2957224A1 - Method of treating prader-willi syndrome - Google Patents
Method of treating prader-willi syndrome Download PDFInfo
- Publication number
- CA2957224A1 CA2957224A1 CA2957224A CA2957224A CA2957224A1 CA 2957224 A1 CA2957224 A1 CA 2957224A1 CA 2957224 A CA2957224 A CA 2957224A CA 2957224 A CA2957224 A CA 2957224A CA 2957224 A1 CA2957224 A1 CA 2957224A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- substituted
- oxytocin receptor
- receptor agonist
- selective oxytocin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052957P | 2014-09-19 | 2014-09-19 | |
| US62/052,957 | 2014-09-19 | ||
| PCT/US2015/049911 WO2016044131A1 (en) | 2014-09-19 | 2015-09-14 | Method of treating prader-willi syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2957224A1 true CA2957224A1 (en) | 2016-03-24 |
Family
ID=54238564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2957224A Pending CA2957224A1 (en) | 2014-09-19 | 2015-09-14 | Method of treating prader-willi syndrome |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10441627B2 (enExample) |
| EP (2) | EP3666258B1 (enExample) |
| JP (3) | JP6599447B2 (enExample) |
| CN (2) | CN112773765A (enExample) |
| CA (1) | CA2957224A1 (enExample) |
| DK (1) | DK3666258T3 (enExample) |
| ES (2) | ES2970059T3 (enExample) |
| FI (1) | FI3666258T3 (enExample) |
| HR (1) | HRP20240166T1 (enExample) |
| HU (1) | HUE065829T2 (enExample) |
| LT (1) | LT3666258T (enExample) |
| PL (1) | PL3666258T3 (enExample) |
| PT (1) | PT3666258T (enExample) |
| RS (1) | RS65144B1 (enExample) |
| SI (1) | SI3666258T1 (enExample) |
| WO (1) | WO2016044131A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS65144B1 (sr) * | 2014-09-19 | 2024-02-29 | Ferring Bv | Postupak za lečenje prader-vilijevog sindroma |
| US20190135859A1 (en) | 2017-08-11 | 2019-05-09 | Ferring B.V. | Method of manufacturing a pharmaceutical composition |
| AU2018312956B2 (en) | 2017-08-11 | 2022-03-10 | Ferring B.V. | Method of manufacturing a pharmaceutical composition |
| WO2019161179A1 (en) * | 2018-02-15 | 2019-08-22 | Ovid Therapeutics Inc. | Methods of treating developmental syndromes with pde10a inhibitors |
| EP3852724A4 (en) | 2018-09-20 | 2022-07-06 | Levo Therapeutics, Inc. | CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE |
| US20200093884A1 (en) | 2018-09-20 | 2020-03-26 | Mark C. Manning | Stable intranasal formulations of carbetocin |
| US20240050494A1 (en) * | 2020-12-18 | 2024-02-15 | The General Hospital Corporation | Probiotics compositions and method of using the same to enhance growth and social function in children |
| WO2022200568A1 (en) | 2021-03-26 | 2022-09-29 | Ot4B | Treatment of dysphagia |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7544662B2 (en) | 1993-06-17 | 2009-06-09 | Carle Development Foundation | Polypeptides useful for appetite suppression |
| US6894026B1 (en) | 2000-01-11 | 2005-05-17 | Atossa Healthcare, Inc. | Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders |
| US20070032410A1 (en) | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
| US9023793B2 (en) | 2006-09-29 | 2015-05-05 | Retrophin, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| EP2167040A1 (en) | 2007-06-07 | 2010-03-31 | MDRNA, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| WO2009033820A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| WO2009033667A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| US20100204107A1 (en) | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of urodilatin as a therapeutic agent |
| JP2010538991A (ja) | 2007-09-11 | 2010-12-16 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | 治療剤としてのｓｆｌｌｒ−ｏｈおよびムラミルジペプチドの使用 |
| RU2496788C2 (ru) | 2008-03-31 | 2013-10-27 | Ферринг Б.В. | Аналоги окситоцина |
| EP2317845A4 (en) | 2008-07-18 | 2011-11-09 | Zafgen Inc | METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON |
| TWI463990B (zh) * | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
| US20120108510A1 (en) | 2010-05-20 | 2012-05-03 | Emory University | Methods of improving behavioral therapies |
| US8853158B2 (en) | 2010-05-25 | 2014-10-07 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods for the treatment of a feeding disorder with onset during neonate development using an agonist of the oxytocin receptor |
| JO3400B1 (ar) * | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| WO2012149472A2 (en) | 2011-04-27 | 2012-11-01 | Ignite Institute For Individualized Health | Methods, compositions, and kits for treating and preventing neurological conditions |
| NZ708175A (en) | 2012-12-21 | 2020-06-26 | Hoffmann La Roche | Peptides as oxytocin agonists |
| WO2014111356A1 (en) * | 2013-01-17 | 2014-07-24 | F. Hoffmann-La Roche Ag | Oxytocin receptor agonists for the treatment of cns diseases |
| CA2949173A1 (en) | 2014-06-03 | 2015-12-10 | Caterina Bissantz | Peptides as oxytocin agonists |
| CR20160562A (es) | 2014-06-06 | 2017-01-06 | Hoffmann La Roche | Péptidos como agonistas de la oxitocina |
| AU2015299118B2 (en) | 2014-08-07 | 2020-07-09 | F. Hoffmann-La Roche Ag | Processes for the preparation of Oxytocin analogues |
| RS65144B1 (sr) | 2014-09-19 | 2024-02-29 | Ferring Bv | Postupak za lečenje prader-vilijevog sindroma |
-
2015
- 2015-09-14 RS RS20240134A patent/RS65144B1/sr unknown
- 2015-09-14 EP EP19216650.2A patent/EP3666258B1/en active Active
- 2015-09-14 EP EP15772107.7A patent/EP3193907B1/en active Active
- 2015-09-14 WO PCT/US2015/049911 patent/WO2016044131A1/en not_active Ceased
- 2015-09-14 HR HRP20240166TT patent/HRP20240166T1/hr unknown
- 2015-09-14 CN CN202110278199.4A patent/CN112773765A/zh active Pending
- 2015-09-14 ES ES19216650T patent/ES2970059T3/es active Active
- 2015-09-14 CA CA2957224A patent/CA2957224A1/en active Pending
- 2015-09-14 PL PL19216650.2T patent/PL3666258T3/pl unknown
- 2015-09-14 FI FIEP19216650.2T patent/FI3666258T3/fi active
- 2015-09-14 DK DK19216650.2T patent/DK3666258T3/da active
- 2015-09-14 CN CN201580049147.2A patent/CN106714819A/zh active Pending
- 2015-09-14 JP JP2017515228A patent/JP6599447B2/ja active Active
- 2015-09-14 HU HUE19216650A patent/HUE065829T2/hu unknown
- 2015-09-14 PT PT192166502T patent/PT3666258T/pt unknown
- 2015-09-14 SI SI201531990T patent/SI3666258T1/sl unknown
- 2015-09-14 LT LTEP19216650.2T patent/LT3666258T/lt unknown
- 2015-09-14 US US15/510,781 patent/US10441627B2/en active Active
- 2015-09-14 ES ES15772107T patent/ES2775425T3/es active Active
-
2019
- 2019-10-02 JP JP2019181930A patent/JP6921154B2/ja active Active
- 2019-10-03 US US16/592,632 patent/US20200129584A1/en not_active Abandoned
-
2021
- 2021-03-15 JP JP2021041334A patent/JP2021098745A/ja active Pending
-
2022
- 2022-11-18 US US18/057,065 patent/US20240082344A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016044131A1 (en) | 2016-03-24 |
| US20240082344A1 (en) | 2024-03-14 |
| EP3666258B1 (en) | 2023-11-15 |
| JP6921154B2 (ja) | 2021-08-18 |
| JP2017532316A (ja) | 2017-11-02 |
| LT3666258T (lt) | 2024-01-10 |
| DK3666258T3 (da) | 2024-02-05 |
| US20200129584A1 (en) | 2020-04-30 |
| FI3666258T3 (fi) | 2024-02-09 |
| EP3666258A1 (en) | 2020-06-17 |
| EP3193907A1 (en) | 2017-07-26 |
| CN106714819A (zh) | 2017-05-24 |
| US20170326200A1 (en) | 2017-11-16 |
| SI3666258T1 (sl) | 2024-04-30 |
| EP3193907B1 (en) | 2020-01-01 |
| ES2775425T3 (es) | 2020-07-27 |
| PL3666258T3 (pl) | 2024-04-08 |
| ES2970059T3 (es) | 2024-05-24 |
| JP2020019790A (ja) | 2020-02-06 |
| HUE065829T2 (hu) | 2024-06-28 |
| CN112773765A (zh) | 2021-05-11 |
| JP2021098745A (ja) | 2021-07-01 |
| JP6599447B2 (ja) | 2019-10-30 |
| RS65144B1 (sr) | 2024-02-29 |
| PT3666258T (pt) | 2024-02-01 |
| HRP20240166T1 (hr) | 2024-04-26 |
| US10441627B2 (en) | 2019-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3666258B1 (en) | Method of treating prader-willi syndrome | |
| JP5677946B2 (ja) | シャルコー・マリー・トゥース病および関連した障害を処置するためのピロカルピンおよびメチマゾールの組み合わせ | |
| AU2023204000A1 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
| JP2021525709A (ja) | 自閉症スペクトラム障害の治療のためのカンナビスベースの組成物 | |
| BR112020003025A2 (pt) | métodos de tratamento de osteoartrite com gel transdérmico de canabidiol | |
| CN106999467A (zh) | 治疗认知减退的方法 | |
| AU2018383098B2 (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | |
| US20170049777A1 (en) | Compositions, methods and uses for the treatment of diabetic neuropathies | |
| EP2754440B1 (en) | Medicinal agent for treating amyotrophic lateral sclerosis or preventing progression of phase of amyotrophic lateral sclerosis | |
| HK1247847A1 (zh) | 四氢-N，N-二甲基-2，2-二苯基-3-呋喃甲胺的对映体(ANAVEX2-73)及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途 | |
| US20040142034A1 (en) | Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators | |
| CA3231407A1 (en) | Treatment of neurological disorders | |
| US11730769B2 (en) | Compositions and methods for Williams Syndrome (WS) therapy | |
| IL303006A (en) | Use of pyridofidine and analogues for the treatment of Rett syndrome | |
| JP6216913B1 (ja) | 医薬組成物 | |
| CN118215480A (zh) | 神经病症的治疗 | |
| JP2017507941A (ja) | 機械的な神経損傷を処置するための新規組成物 | |
| EP1621193A2 (en) | Treatment of non-painful bladder disorders using alpha2-delta-subunit calcium channel modulators | |
| ZA200505142B (en) | Methods of treating non-painful bladder disorders using &2.d subunit calcium channel modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200911 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240903 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240903 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240903 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20241015 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250902 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250902 |
|
| C11 | Application revival requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED Effective date: 20251009 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251009 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251010 |
|
| C13 | Application revived following an application revival request |
Free format text: ST27 STATUS EVENT CODE: A-6-2-C10-C13-C102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUIREMENTS DEEMED COMPLIANT FOR ALL ABANDONMENT REASONS Effective date: 20260507 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260507 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260507 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260507 Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260507 |